![]() | DCGI approves market authorisation for SII's Covid vaccine Covovax as heterologous booster doseCovovax is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation. |
![]() | Hesitancy, short supply dent vaccination coverage in TNState has run out of Corbevax that is administered on kids belonging to 12-14 age group |
![]() | Vax deal: Karnataka HC relief for Bharat BiotechJustice M Nagaprasanna said Writ petition for recovery of money by a private entity from another private entity arising out of a private contract cannot be entertained. |
![]() | Government: Reports of forced nod to Covaxin misleadingIn a statement, the health ministry said that there had been media reports claiming that Bharat Biotech “had to skip certain processes” and “speed” up clinical trials due to political pressure. |
![]() | 'Targeted narrative': Govt, Bharat Biotech deny political pressure led to Covaxin's early approvalIn a statement, the health ministry said that there had been media reports claiming that Bharat Biotech “had to skip certain processes” and “speed” up clinical trials due to political pressure. |
![]() | 50 million doses of Covaxin set to expire in early 2023 due to poor demandDue to lack of product demand, production stoppage of Covaxin- a two-dose jab, was initiated by Bharat Biotech earlier in 2022. |
![]() | Government nod for Corbevax as booster for adults vaccinated with Covishield, Covaxin soonThe approval will be based on the recommendations made by the COVID-19 Working Group of the National Technical Advisory Group on Immunisation (NTAGI) last week. |
![]() | Govt panel recommends Corbevax as booster for adults vaccinated with Covishield, CovaxinIndia's first indigenously developed RBD protein subunit vaccine Corbevax is currently being used to inoculate children in the age group of 12 to 14 years. |
![]() | Covaxin booster safe, necessary as it ensures persistent immunity: ICMR studyThe study said that the administration of the third dose of BBV152 increased neutralisation titers against both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, Delta Plus and Omicron) |
![]() | NTAGI panel recommends use of Covid vaccines Corbevax, Covaxin for kids aged 5-12 yearsHowever, there was no decision on introducing these vaccines in the vaccination programme. |
![]() | Covaxin booster dose generates 25-fold rise in antibodies: ICMR studyThe year-long longitudinal cohort study started in January last year and continued till March this year. A total of 304 healthcare workers (HCWs) were included in the study. |
![]() | Immunisation body likely to consider Corbevax as booster for those jabbed with Covishield, CovaxinThe Drugs Controller General of India (DCGI) on June 4 approved Corbevax as a precaution dose for those aged 18 and above. |
![]() | DCGI to review Serum Institute's applications for Covovax use in kids aged 2 to 7 yrs, 7 to 11 yrsThe expert panel in its last meeting in April had sought more data from SII following its application seeking the emergency use authorization of Covovax for seven to 11 years. |
![]() | ‘Covaxin booster improves efficacy against two variants’: Bharat BiotechA booster dose of Covaxin enhances vaccine effectiveness against Delta and Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech said. |
![]() | Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, find ICMR studyThe findings of the study have been published on Tuesday on bioRxiv, a pre-print server and have not been peer reviewed. |
![]() | NTAGI to discuss allowing Corbevax as booster for those vaccinated with Covishield, Covaxin: SourcesThe Drugs Controller General of India (DCGI) on Sunday approved Corbevax for the precaution dose for those aged 18 and above. |
![]() | Germany to recognise Covaxin for travel purpose from June 1, says envoyIn November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin. |
![]() | FDA lifts hold on Covaxin's clinical trials in USThe FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab. |
![]() | Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-oldPresently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose. |
![]() | Bharat Biotech's Covaxin gets emergency approval for 6-12 age groupThe company said it conducted clinical trials in the paediatric population between June 2021 to September 2021 and results have shown robust safety, reactogenicity, and immunogenicity. |
Latest
Mughal Gardens in Rashtrapati Bhavan renamed as 'Amrit Udyan'
Costa Rican President meets Gautam Adani in Davos, talks about Dry Canal project
BJP's Mahila Morcha launches 'Sushma Swaraj Award' for distinguished women achievers
Indus Water Treaty a technical matter, commissioners of both countries will talk: Jaishankar
Mumbai: Tension in Tata Institute of Social Sciences as students screen BBC documentary on Modi
India beat South Africa 5-2 to finish joint ninth in FIH Men's WC